Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.

World J Gastroenterol

Hee Chul Nam, Bohyun Jang, Myeong Jun Song, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul 06591, South Korea.

Published: October 2016

Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia (conventional TACE). Recently, drug-eluting beads (DC Beads) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drug-eluting beads for the treatment of HCC and discuss future therapeutic possibilities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083790PMC
http://dx.doi.org/10.3748/wjg.v22.i40.8853DOI Listing

Publication Analysis

Top Keywords

drug-eluting beads
12
transarterial chemoembolization
8
hepatocellular carcinoma
8
tace drug-eluting
8
treatment hcc
8
chemotherapeutic agent
8
beads
6
treatment
5
chemoembolization drug-eluting
4
beads hepatocellular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!